Manuel Espinoza-Gutarra, MD
Hematology & Oncology · Birmingham, ALNPI 1588015515
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,810 of the $30,318 with a category attached, or 81.8%. 17 manufacturers reported payments, led by Incyte Corporation at 50.3% of the total. 2025 is the largest year on record at $27,479, more than ten times the $105 reported in 2020.
Across 50 payments — averaging $606.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$15K
- Gamida Cell Inc.$9K
- Stemline Therapeutics Inc.$2K
- Daiichi Sankyo Inc.$650
- AbbVie$600
- National Marrow Donor Program$488
- plus $2K from 11 others
Across 16 payments — averaging $4727.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$47K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- National Marrow Donor Program$10K
What the payments were for
- Consulting fees$24,81082%
- Travel & lodging$2,91610%
- Food & beverage$1,9356%
- Education$6572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 20 | $15,246 |
| Gamida Cell Inc. | 3 | $9,215 |
| Stemline Therapeutics Inc. | 1 | $2,340 |
| Daiichi Sankyo Inc. | 1 | $650 |
| AbbVie | 1 | $600 |
| National Marrow Donor Program | 2 | $488 |
| Sobi, Inc | 6 | $469 |
| Seagen Inc. | 4 | $421 |
| Amgen | 4 | $201 |
| Bristol Myers Squibb | 1 | $125 |
| Adaptive Biotechnologies Corporation | 1 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Rigel Pharmaceuticals, Inc. | 1 | $84 |
| Epizyme, Inc. | 1 | $83 |
| GSK | 1 | $78 |
| Genentech, Inc. | 1 | $78 |
| Corcept Therapeutics | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,318 in reported general payments places this provider in the 85th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrevymisLetermovir | 11 | $75,595 |
| Posaconazole | 22 | $47,927 |
| VenclextaVenetoclax | 57 | $47,755 |
| Voriconazole | 45 | $21,883 |
| EliquisApixaban | 16 | $9,339 |
| Atovaquone | 11 | $6,874 |
| Acyclovir | 91 | $970 |
| Levofloxacin | 70 | $713 |
| Ondansetron Hcl | 15 | $449 |
| Potassium Chloride | 31 | $390 |
| Oxycodone Hcl | 34 | $325 |
| Magnesium Sulfate | 20 | $322 |
| Prednisone | 24 | $181 |
| Gabapentin | 16 | $176 |
| Trazodone Hcl | 15 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $600 | $47,75557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.